Skip to main content
. Author manuscript; available in PMC: 2021 Apr 15.
Published in final edited form as: Clin Cancer Res. 2020 Jul 28;26(20):5424–5437. doi: 10.1158/1078-0432.CCR-20-0851

Figure 2. Renal/hepatic clearance and biodistribution of 89Zr-DFO-Gef-C’ dots (DPR 40) in healthy mice after i.v. administration.

Figure 2.

a) Biodistribution of 89Zr-DFO-Gef-C’ dots in major organs and tissues on day 7, expressed in terms of %ID (n=3; error bars: mean±SD). Inset shows the cumulative clearance measurements of 89Zr-DFO-Gef-C’ dots in urine and feces at various p.i. time points (n=3; error bars: mean±SD). b) Biodistribution of 89Zr-DFO-Gef-C’ dots in healthy mice (n=3) at 4, 24 and 72 h post-injection.